Back to search

University of West Attica

Συγκριτική μελέτη ποιότητας ζωής ασθενών με καρκίνο πνεύμονα υπό χημειοθεραπεία δεύτερης γραμμής και ανοσοθεραπεία

Abstract

dc:description

Introduction: Non-small cell lung cancer (NSCLC) presents with a range of symptoms and is associated with a poor prognosis and significantly reduced quality of life. Both immunotherapy (IMT) and chemotherapy (CMT), although they improve survival, are still associated with reduced functionality due to the toxicity they cause. Aim: The aim of the study was to assess the quality of life of patients with NSCLC receiving second-line CMT versus those receiving second-line IMT, to assess symptoms related to the disease and its treatment, and to investigate the frequency of psychological symptoms, such as anxiety and depression. Materials and Methods: This is a comparative, prospective, non-randomized follow-up study. In total, with convenience sampling, 111 patients with NSCLC were collected, 61 under CMT and 50 under second-line IMT, from two hospitals in Athens in the period January 2020 – December 2021. Criteria for participation in the study were age over 18 years, histological documented diagnosis of NSCLC, receiving exclusively second-line CMT or IMT, satisfactory knowledge and understanding of the Greek language and satisfactory cognitive function. All patients completed a demographic data form, the Eastern Cooperative Oncology Group (ECOG) functional assessment scale (value range 0-4), the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) (value range 0-100), the Lung Cancer Symptom Scale (LCSS) (value range 0-100) and the Hospital Anxiety and Depression Scale (HADS) (value range 0-21). Results: The majority of the sample was men (75.7%), with a mean age of 66.5±9.2 years. The mean value of functionality based on the ECOG scale was 0.8±1. According to the EORTC QLQ-C30 scale the mean value of the general health status and all dimensions of functioning were above 50 points, with the highest values observed in cognitive (mean value: 92.2±15.1), emotional (mean value: 85.5±17.2) and physical functioning (mean value: 72.6±27.5). The mean score for all symptom subscales of the EORTC QLQ-C30 scale was below 50 points. The highest score was observed in insomnia (mean: 39.3±33), loss of appetite (mean: 32.2±32.5) and fatigue (27.3±26.5) and the lowest was observed in nausea /vomiting (mean: 7.6±11.9) and diarrhea (mean: 7.8±18.2). The mean LCSS symptom scale total score was 30.6±19. According to the HADS scale, the average depression score was 5.7±5.4 and anxiety 4.5±4.8. By type of treatment, there was homogeneity in patient demographic and clinical characteristics. According to the EORTC QLQ-C30 scale, the IMT group reported statistically significantly better general health status from the 3rd to the 5th treatment cycle, with the difference between the groups becoming larger at the 5th cycle (p=0.007). The IMT group reported higher emotional (p<0.005) and cognitive functioning (p<0.005) from cycle 2 and higher role functioning and social functioning from cycle 3 onwards (p<0.05). Fatigue and insomnia remained stable in the IMT group, while significantly increased in the CMT group (p<0.005). Constipation was reduced in the IMT group (p=0.023), without change in the CMT group (p=0.366). Diarrhea was significantly increased in the IMT group (p=0.001), without change in the CMT group (p=0.278). According to the LCSS scale, across all treatment cycles, the IMT group reported less symptom distress (p<0.05). Depressive symptoms were statistically significantly higher in patients who received CMT from the 4th cycle onwards (p<0.05), but in any of the groups the value did not exceed the critical threshold of 7 points. In the anxiety subscale there was no statistically significant difference between the groups and from the 3rd cycle onwards there was a decrease in both groups (p=0.014). Patient outcome differed significantly between the two groups. In the CMT group, the relapse rate was 2 times higher (55.7% vs. 26%, p=0.006) and the death rate was 4 times higher (26.2% vs. 6%, p=0.005), compared to the IMT group. Conclusions: In patients with NSCLC, IMT is associated with more improved quality of life, less burden of symptoms, and better survival compared to those receiving CMT, while anxiety and depression do not appear to be a serious problem in either patient group. The present study was the first attempt to investigate differences in quality of life between treatment groups in Greek patients with NSCLC and highlights the importance of a multidimensional approach and the necessity of multicenter studies to identify factors that influence self-reported quality of life over time.

Degree

thesis:*
Grantor dc:publisher
University of West Attica
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Stylianou, Christos
  • Στυλιανού, Χρίστος

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58006

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Stylianou, Christos; Στυλιανού, Χρίστος. Συγκριτική μελέτη ποιότητας ζωής ασθενών με καρκίνο πνεύμονα υπό χημειοθεραπεία δεύτερης γραμμής και ανοσοθεραπεία. University of West Attica, 2024. http://hdl.handle.net/10442/hedi/58006